Abstract
Background & objectives In Latin America, Chagas disease is endemic, with high prevalence in rural indigenous communities and increasing prevalence in urban areas due to migration from rural areas with active vector transmission. The objective of the work was to assess differences in the prevalence of Chagas disease in urban and rural moqoit communities of the south of Gran Chaco, Santa Fe province, Argentina.
Methods A seroprevalence study was conducted in six moqoit populations. Belonging to an urban community was considered as an exposure variable, whereas seropositivity for Chagas disease was considered as an outcome variable
Results The results showed that 9.26% of the 702 volunteers evaluated and 3.50% of women of childbearing potential were seropositive. The prevalence of Chagas disease in urban communities was 6.41 times higher than in rural communities.
Interpretation & conclusions The seroprevalence found in the moqoit community is higher than that estimated for the general population of the same region, with greater impact in the urban area than in the rural area. The decline of vector transmission in the rural area could be related to the conservation of ancestral practices and the expansion of the agricultural model.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
CAI+D-UNL
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The project was evaluated and approved by the Ethics and Security Advisory Committee in Research of the School of Biochemistry and Biological Sciences of the Universidad Nacional del Litoral, Santa Fe, Argentina (Act No. 03/12)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
There are not any supplement data available
